Wellington Management Group LLP Sells 3,026 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Wellington Management Group LLP trimmed its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 6.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 41,803 shares of the specialty pharmaceutical company’s stock after selling 3,026 shares during the quarter. Wellington Management Group LLP owned 0.07% of Jazz Pharmaceuticals worth $5,148,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Fuller & Thaler Asset Management Inc. boosted its stake in shares of Jazz Pharmaceuticals by 117.4% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 939,351 shares of the specialty pharmaceutical company’s stock valued at $115,681,000 after purchasing an additional 507,234 shares during the last quarter. Darwin Global Management Ltd. bought a new stake in shares of Jazz Pharmaceuticals in the 4th quarter worth $59,668,000. Dimensional Fund Advisors LP grew its position in Jazz Pharmaceuticals by 18.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company’s stock valued at $250,619,000 after buying an additional 320,724 shares during the period. Ameriprise Financial Inc. grew its position in Jazz Pharmaceuticals by 20.9% during the fourth quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company’s stock valued at $225,076,000 after buying an additional 315,608 shares during the period. Finally, GMT Capital Corp grew its position in Jazz Pharmaceuticals by 140.0% during the fourth quarter. GMT Capital Corp now owns 508,800 shares of the specialty pharmaceutical company’s stock valued at $62,659,000 after buying an additional 296,800 shares during the period. 89.14% of the stock is owned by institutional investors.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the company’s stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $116.35, for a total transaction of $116,350.00. Following the completion of the transaction, the chief executive officer now directly owns 439,307 shares in the company, valued at approximately $51,113,369.45. This represents a 0.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Seamus Mulligan acquired 100,000 shares of Jazz Pharmaceuticals stock in a transaction on Friday, May 9th. The shares were bought at an average price of $98.26 per share, with a total value of $9,826,000.00. Following the completion of the transaction, the director now directly owns 100,000 shares of the company’s stock, valued at $9,826,000. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders sold 13,123 shares of company stock worth $1,772,966 over the last three months. 4.20% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ:JAZZ opened at $110.32 on Wednesday. Jazz Pharmaceuticals plc has a fifty-two week low of $95.49 and a fifty-two week high of $148.06. The business has a 50-day simple moving average of $108.95 and a two-hundred day simple moving average of $121.18. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The firm has a market cap of $6.80 billion, a price-to-earnings ratio of 15.54, a price-to-earnings-growth ratio of 1.04 and a beta of 0.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing the consensus estimate of $4.65 by ($2.97). The business had revenue of $897.84 million during the quarter, compared to the consensus estimate of $984.16 million. Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. The company’s revenue for the quarter was down .5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.68 earnings per share. On average, analysts expect that Jazz Pharmaceuticals plc will post 16.96 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have weighed in on JAZZ. Needham & Company LLC reiterated a “buy” rating and set a $202.00 target price on shares of Jazz Pharmaceuticals in a research report on Tuesday. Wells Fargo & Company raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $130.00 to $170.00 in a research note on Thursday, February 13th. Robert W. Baird decreased their price target on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 7th. JPMorgan Chase & Co. raised their target price on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. Finally, Truist Financial lifted their price target on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a report on Thursday, March 6th. Two equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat, Jazz Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $182.93.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.